David Liew drdavidliew
4 years 10 months ago
"GCA is not a single, monolithic disease"
- Christian Dejaco, rightfully asking why we don't stratify treatment/trials in GCA
#ACR21 PMR/GCA Study Group @RheumNow @Sarah_L_Mackie @profbdasgupta @EBRheum @RichardPAConway @SattuiSEMD @drceowen
Januse kinase (JAK) inhibitors are targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) that have risen in popularity as earlier treatment options for rheumatoid arthritis. With multiple JAK inhibitors available in the United States (tofacitinib, baricitinib, and upadacitinib), patients who fail one treatment option have the ability to switch to another agent or change to biologic therapy.
Dr. John Cush RheumNow
4 years 10 months ago
RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow and its Faculty.
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
Eric Dein ericdeinmd
4 years 10 months ago
#ACR21 Abs#0819. RheumTAP real-world cohort of pts tapering Rx in remission on RA
▶️ Pts tapering 7.6x ⬆️ likely to flare in f/u
Great convo soon on @Rheumnow re: tapering studies. @davidliew asks how many more times do we need to see drug w/d fail?
https://t.co/BiZSM7yp7o https://t.co/iDXGVpFZzB
Eric Dein ericdeinmd
4 years 10 months ago
#ACR21 Rheum Pearls and Secrets
Not all (or most) ulcers is Behcet's! Here's a great approach to use in clinic. Jason Kolfenbach: "Sometimes, taking off the mask is worth it"
@Rheumnow https://t.co/OEBgf1eFhd
Eric Dein ericdeinmd
4 years 10 months ago
#ACR21. Powerful patient perspective by Amy Barron, RN and rheumatic patient
⭐️"I found hope advocating for arthritis" and found meaning in advocacy.
▶️ Consider talking to your patients about getting involved in ACR Advocacy to give purpose & community.
@ACRheumDC @CreakyJoints https://t.co/2mJRaShZQQ
Dr. Rachel Tate uptoTate
4 years 10 months ago
Females axSpA pts presented w/ higher disease burden (fatigue/tiredness, & spinal pain at night.) Female axSpA pts achieved sign/symptom improvement with IXE later than male axSpA pts. Abs 0934 #ACR21 #RheumNow@RheumNow https://t.co/EGXnfeF6KQ https://t.co/TDF5zxtca7
Bella Mehta bella_mehta
4 years 10 months ago
Oral Calcitonin not recommended for OA - studies did not show efficacy
Strontium Ranelate study below was considered a positive study in KOA with efficacy but had Cardiovascular toxicity - now off the market. https://t.co/gcYH9xoxeo
